Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Base-Catalyzed Diversity-Orientated Synthesis of Tetra-/Dihydrothiophenecarboxamides and Preliminary Evaluation as Antifungal Agents.

The Journal of organic chemistry·2026
Same author

Post-Marketing Surveillance of Adverse Events Following 23-Valent Pneumococcal Polysaccharide Vaccination - China, 2021-2024.

China CDC weekly·2026
Same author

Emerging enzymatic strategies for the synthesis of α-tertiary amino acids.

Communications chemistry·2026
Same author

Structural Hairpin Anchoring-Mediated TtAgo Activity Regulation for Programmable Biosensing.

Analytical chemistry·2026
Same author

SETD7 depletion enhances white adipose browning and ameliorates metabolic disorders in obese mice.

Cell death and differentiation·2026
Same author

Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma.

Pharmacological research·2026

Related Experiment Video

Updated: Jun 5, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Inulin-Type Hexasaccharide Improves Vascular Dementia by Modulating Sphingomyelin Lipid Metabolism.

Jiayao Liu1, Jinghuan Wang1, Jialin Zhao1

  • 1Phenome Research Center of TCM, Department of Traditional Chinese Medicine, Shanghai Pudong Hospital; Pharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai, 201203 China.

Phenomics (Cham, Switzerland)
|June 4, 2026
PubMed
Summary

Inulin-type hexasaccharide (IHS) from traditional Chinese medicine improves cognitive function in vascular dementia (VaD) mice by reducing neuroinflammation and modulating sphingolipid metabolism, offering a potential new treatment for VaD.

Keywords:
Inulin-type hexasaccharideMetabolomicsProteomicsSphingosineVascular dementia

More Related Videos

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

Related Experiment Videos

Last Updated: Jun 5, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

Area of Science:

  • Neuroscience
  • Pharmacology
  • Metabolomics

Background:

  • Vascular dementia (VaD) is a prevalent neurodegenerative disease with limited therapeutic options.
  • Traditional Chinese herbal medicine, Morinda officinalis (BaJiTian), contains compounds with potential therapeutic benefits.
  • Inulin-type hexasaccharide (IHS) has demonstrated antidepressant effects in various animal models.

Purpose of the Study:

  • To investigate the therapeutic potential of IHS in a mouse model of VaD.
  • To elucidate the underlying mechanisms of IHS action in VaD.

Main Methods:

  • Administration of IHS to VaD mice.
  • Assessment of cognitive function, histological changes, and cerebral blood flow.
  • Analysis of neuroinflammation and apoptosis markers.
  • Comprehensive metabolomic and proteomic analyses of serum, fecal, and brain tissues.

Main Results:

  • IHS significantly improved cognitive impairment in VaD mice.
  • IHS alleviated histological damage, enhanced cerebral blood flow, and reduced neuroinflammation and apoptosis.
  • Metabolomic and proteomic analyses revealed that IHS modulates sphingolipid, glycerophospholipid, and pyruvate metabolism.
  • Specifically, IHS decreased ceramide accumulation in the brain via the sphingolipid metabolism pathway.

Conclusions:

  • IHS demonstrates significant therapeutic effects in a VaD mouse model.
  • The mechanism involves the modulation of sphingolipid metabolism, reducing ceramide accumulation.
  • IHS represents a promising therapeutic candidate for vascular dementia.